keyboard_arrow_up

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trials Market Review H1 2015

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2015″ provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
Listings of discontinued trials (suspended, withdrawn and terminated)

Inquire more about this report: http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=268952 .

This is a premium report priced at US$2500 for a single user PDF.


Reasons To Buy

Understand the dynamics of a particular indication in a condensed manner
Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
Obtain discontinued trial listing for trials across the globe
Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

List of Tables

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Region, 2015* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2015* 24
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2015* 30
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015* 31
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ZonMw, 2015* 32
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2015* 33
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Parkway Pantai Limited, 2015* 34
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Multiplex Pharma Holdings LLC, 2015* 35
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015* 36
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by ArmaGen Technologies, Inc., 2015* 37
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015* 38
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Los Angeles Biomedical Research Institute, 2015* 39
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2015* 40
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2015* 41
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas Southwestern Medical Center at Dallas, 2015* 42
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2015* 43
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Hamburg-Eppendorf, 2015* 44
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2015* 45
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2015* 46
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2015* 47